KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Cash: 2020-2025

Historic Change in Cash for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to $133.3 million.

  • Recursion Pharmaceuticals' Change in Cash rose 384.09% to $133.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $231.3 million, marking a year-over-year increase of 498.89%. This contributed to the annual value of $201.6 million for FY2024, which is 227.85% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Change in Cash stood at $133.3 million for Q3 2025, which was up 439.94% from $24.7 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Change in Cash's 5-year high stood at $423.8 million during Q2 2021, with a 5-year trough of -$238.0 million in Q3 2021.
  • In the last 3 years, Recursion Pharmaceuticals' Change in Cash had a median value of -$19.6 million in 2023 and averaged $9.8 million.
  • In the last 5 years, Recursion Pharmaceuticals' Change in Cash tumbled by 2,615.00% in 2023 and then surged by 3,863.80% in 2024.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Change in Cash stood at -$109.6 million in 2021, then skyrocketed by 185.97% to $94.2 million in 2022, then slumped by 95.52% to $4.2 million in 2023, then soared by 3,863.80% to $167.2 million in 2024, then soared by 384.09% to $133.3 million in 2025.
  • Its Change in Cash stands at $133.3 million for Q3 2025, versus $24.7 million for Q2 2025 and -$93.9 million for Q1 2025.